Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
Survey
We asked 40 pharma leaders, what area do you think will see increased regulatory attention and enforcement in 2013?
Foreign APIs 30%

GMP inspections

18%
Counterfeit medicines 30%
Social media and digital marketing 9%
Other 13%

Talk to us:
jupton@advanstar.com

Advertise with us:
Dtaylor-higgins@advanstar.com

15 January, 2013
In this Issue
Layoffs in 2013: Calmer for Pharma?
In Pharm Exec's new video, Reid Paul assesses the redundancy statistics for 2012 and asks, is pharma now 'right-sized?' ...View the video
The JP Morgan Conference: Suits Take San Francisco
The usual suspects lurked at this year's annual J.P. Morgan Healthcare Conference, but newcomers like Walgreens and not-so-pharma companies like Life Technologies packed the presentation halls and corridors ... Read more
All's Fair in Brazil's War on AIDS
Brazil's deal to domestically produce a generic version of the BMS AIDS drug atazanavir has met with resistance from the industry — but the Health Ministry remains defiant ... Read more
EMA's Dr Guido Rasi: The Puzzle Master
An exclusive interview with Europe’s chief regulator ... Read more
Guide to Strategic Outsourcing
Inside Outsourcing, our new eBook featuring the latest articles, analyses and opinion on optimizing CRO/CMO relationships, is available for free download now ... Read more
Also in this issue
US Drug Approvals 2012 — Best Year for 16 Years
The African Markets Pharma Can't Ignore
A Glimpse of Global Health in 2030